Abbreviations {#nomen0010}
=============

3V

:   third ventricle

ARH

:   arcuate nucleus

BAT

:   brown adipose tissue

Cidea

:   cell death-inducing DFFA-like effector A

CT

:   cycle of threshold

DIO

:   diet-induced obese

Dio2

:   iodothyronine deiodinase 2

eWAT

:   epididymal white adipose tissue

GTT

:   glucose tolerance test

HFHS

:   high-fat, high-sugar

Hprt

:   hypoxanthine-guanine phosphoribosyltransferase

IHC

:   immunohistochemistry

i.p.

:   intraperitoneal

iWAT

:   inguinal white adipose tissue

ME

:   median eminence

MPO

:   medial preoptic nucleus

NE

:   norepinephrine

PBS

:   phosphate-buffered saline

PFA

:   paraformaldehyde

Pgc-1α

:   peroxisome proliferator-activated receptor gamma, coactivator 1 alpha

PIP2

:   phosphatidylinositol 4,5-bisphosphate

Pirt

:   phosphoinositide interacting regulator of transient receptor potentials

Pirt−/−

:   Pirt deficient

Ppib

:   peptidylprolyl isomerase B

Prdm16

:   PR domain-containing 16

PVH

:   paraventricular hypothalamic nucleus

qPCR

:   quantitative real-time PCR

RER

:   respiratory exchange ratio

s.c.

:   subcutaneous

TBS

:   tris-buffered saline

TRPM8

:   transient receptor potential melastatin 8

TRPV1

:   transient receptor potential vanilloid 1

UCP1

:   uncoupling protein 1

VMH

:   ventromedial hypothalamic nucleus

WT

:   wild-type

1. Introduction {#sec1}
===============

The ongoing global obesity epidemic is a consequence of a persistent positive energy balance emerging when food intake chronically exceeds energy expenditure [@bib1]. Since the evidence of active brown adipose tissue (BAT) in humans, targeting of this metabolically active tissue has surfaced as a promising therapeutic intervention to keep energy balance and body weight in check [@bib2], [@bib3], [@bib4], [@bib5]. Physiologically, BAT thermogenesis increases with prolonged exposure to cold, enabling mammals to maintain core body temperature upon fluctuations in environmental temperatures [@bib6]. During this process of adaptive thermogenesis, norepinephrine (NE) released from sympathetic neurons activates β3-adrenoceptors on the cell surface of the brown adipocytes, which initiates a signaling cascade that results in activation of the uncoupling protein 1 (UCP1) and dissipation of heat at the expense of ATP production [@bib6], [@bib7], [@bib8], [@bib9]. In contrast to the indirect activation of UCP1-dependent non-shivering thermogenesis upon cold temperatures, there is evidence to suggest direct cold-sensing by brown adipocytes via transient receptor potential melastatin 8 (TRPM8) [@bib10].

It is well established that TRPM8 channels are expressed in dorsal root ganglia, and they are activated upon temperatures below ∼26 °C [@bib11], [@bib12]. The observation that TRPM8 channels can also be activated by exogenous ligands such as menthol and icilin has ignited interest in exploring a role for TRPM8 targeting in the pharmacological treatment of obesity [@bib11], [@bib12]. Notably, activation of TRPM8 channels with icilin acutely caused an increase in energy expenditure in mice, and long-term treatment with dietary menthol or subcutaneous injections of icilin prevents weight gain or lowers body weight in diet-induced obese (DIO) mice [@bib10], [@bib13]. Moreover, icilin treatment in mice housed at thermoneutrality, and in which BAT thermogenesis is at a minimum, leads to the re-expression of UCP1 protein in the BAT [@bib13]. Although it is not clear whether the effects of TRPM8 activation on whole-body thermogenesis are consequential to direct effects on adipocytes [@bib10] or are mediated indirectly [@bib13], [@bib14], together, these findings suggest that pharmacological targeting of TRPM8 might be a viable anti-obesity strategy and thus underscore the imperative task of parsing out the molecular mechanisms connecting TRPM8 to energy expenditure and BAT thermogenesis.

Phosphoinositide interacting regulator of TRPs (Pirt) was established as an endogenous regulator of TRP channels, including heat-sensing TRP vanilloid 1 (TRPV1) [@bib15] and more recently cold-sensing TRPM8 [@bib16], [@bib17]. Pirt is a membrane protein predominantly expressed in dorsal root ganglia that increases sensitivity to exogenous TRPM8 stimulation in conjunction with the canonical cellular signal molecule phosphatidylinositol 4,5-bisphosphate (PIP2) [@bib16], [@bib18]. Pirt deficient (Pirt^−/−^) mice have an impaired response to cold, indicating that the protein is involved in temperature sensation/regulation [@bib16]. Moreover, Pirt^−/−^ mice display a blunted behavioral response to icilin [@bib16], suggesting that Pirt is required for both physiological and pharmacological TRPM8-based signaling.

Here we report that Pirt deficient female mice have an increased body weight and impaired glucose tolerance relative to wild-type (WT) mice. This increased susceptibility to develop obesity and glucose intolerance in female Pirt^−/−^ mice is abrogated in the presence of a high-fat, high-sugar (HFHS) diet as well as in male mice irrespective of the dietary regime. Finally, we reveal that Pirt is dispensable for TRPM8-induced BAT thermogenesis *in vivo*.

2. Material and methods {#sec2}
=======================

2.1. Animal housing and phenotyping conditions {#sec2.1}
----------------------------------------------

The generation of the Pirt^−/−^ mouse is described elsewhere [@bib15]. The cohorts were generated from homozygous breeding. Mice were maintained at 23 ± 1 °C, constant humidity, and on a 12 h light--dark cycle with free access to food and water. Phenotypic analysis of Pirt^−/−^ mice and WT mice was initiated at the age of 8 weeks. A male and female cohort of eight WT and eight Pirt^−/−^ mice was phenotypically monitored on a standard chow diet. Another cohort of eight male and female WT and Pirt^−/−^ mice was switched from chow to HFHS diet (58% kcal from fat; D12331, Research Diets, New Brunswick, NJ, USA) at the age of 8 weeks. Body weight and food intake were assessed on a weekly basis until the age of 25 weeks. All procedures were approved by the Animal Use and Care Committee of Bavaria, Germany.

2.2. Glucose tolerance test {#sec2.2}
---------------------------

At 26 weeks of age, a glucose tolerance test was performed. Mice were fasted for 6 h and challenged with a bolus injection of glucose (5 μl/g body weight, intraperitoneal (i.p.)). Male mice on a chow and HFHS diet received 1.5 g glucose/kg body weight; female mice on a chow and HFHS diet were injected with 2.0 g glucose/kg body weight. Blood glucose was measured from the tail veins at the indicated timepoints with a handheld glucometer (Abbott GmbH & Co. KG, Wiesbaden, Germany).

2.3. Energy metabolism studies {#sec2.3}
------------------------------

Energy expenditure, respiratory exchange ratio (RER), and home-cage locomotor activity were assessed in 27-weeks old chow-fed female WT and Pirt^−/−^ mice using a combined indirect calorimetry system (TSE Systems, Bad Homburg, Germany). After a 24 h adaptation phase, oxygen consumption and carbon dioxide production were measured every 10 min for up to 61 h.

2.4. Whole body composition {#sec2.4}
---------------------------

Whole body composition (fat and lean mass) was measured using nuclear resonance technology (EchoMRI, Houston, TX, USA).

2.5. Acute icilin challenge {#sec2.5}
---------------------------

Female chow-fed WT and Pirt^−/−^ mice received a single injection of phosphate-buffered saline (PBS) or icilin (2 μmol/kg body weight; 5 μl/g body weight injection volume, subcutaneous (s.c.); Cat.No. 36945-98-9 (ROE01), Bicoll, Planegg, Germany), while oxygen consumption, carbon dioxide production, and locomotor activity were registered with indirect calorimetry.

2.6. Immunohistochemistry {#sec2.6}
-------------------------

WT and Pirt^−/−^ male mice were anesthetized with carbon dioxide and perfused by intracardiac puncture with saline and fixed with 4% paraformaldehyde (PFA) solution. Brains were harvested, kept in 4% PFA for 24 h at 4 °C, transferred to 30% sucrose, and sliced on a cryostat in the coronal plane at 30 μm. The slices were blocked in 0.25% gelatin and 0.5% Triton X-100 in tris-buffered saline (TBS) for 1 h and incubated with Pirt antibody (1:500, Biorbyt LLC, San Francisco, CA, USA; orb158159) diluted in the blocking solution (TBS containing 0.25% gelatin and 0.5% Triton X-100) at 4 °C, overnight. Sections were washed 3 times in TBS and incubated with Alexa Fluor^®^ 568 (1:500, Thermo Fisher Scientific, Waltham, MA, USA; A-11011) diluted in the blocking solution for 1 h at room temperature and stained with DAPI solution (1:3000, Thermo Fisher Scientific; 62248) for 3 min. Sections were washed in TBS, dried, and mounted with Slowfade Gold mounting medium (Thermo Fisher Scientific). Image stacks (30 μm thick) were collected through the *z*-axis at an interval of 2 μm using a Leica SP5 scanning confocal microscope equipped with a 20× objective and final images obtained by maximum intensity projection of the *z*-stack.

2.7. Gene expression analysis {#sec2.7}
-----------------------------

For expression profiling of Pirt, tissues were collected from male C57Bl/6j WT and Pirt^−/−^ mice and immediately frozen on dry ice. RNA was extracted using QIAzol^®^ Lysis Reagent (Qiagen, Hilden, Germany), and cDNA was synthesized using a QuantiTect Reverse Transcription Kit (Qiagen). Gene expression was profiled with quantitative real-time PCR (qPCR) using SYBR^®^ Green Real-Time PCR master mix (Life Technologies GmbH, Darmstadt, Germany). The relative expression of the Pirt gene (Forward primer 5′ACCACACCCAAAAGCAACTG′3; Reverse primer 5′GCCCTATCATCCTGAGCACT′3) was normalized to the reference genes hypoxanthine-guanine phosphoribosyltransferase (Hprt) (Forward primer 5′AAGCTTGCTGGTGAAAAGGA′3; Reverse primer 5′TTGCGCTCATCTTAGGCTTT′3) and peptidylprolyl isomerase B (Ppib) (Forward primer 5′GCATCTATGGTGAGCGCTTC′3; Reverse primer 5′CTCCACCTTCCGTACCACAT′3). The threshold cycle method (2^−ΔΔCT^) of comparative PCR was used to analyze the results.

2.8. Statistical analysis {#sec2.8}
-------------------------

Differences between genotypes or treatment were assessed by two-way ANOVA followed by Bonferroni\'s post hoc analysis as appropriate or an unpaired two-tailed Student\'s *t*-test. All results are presented as mean ± s.e.m. *P* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Pirt expression {#sec3.1}
--------------------

Pirt is reported to be highly expressed in dorsal root ganglia and trigeminal neurons and to a lesser extent in enteric and sympathetic neurons [@bib15]. Aiming to uncover a role for Pirt in energy metabolism, we here investigated Pirt expression in key metabolic tissues including adipose tissue and the hypothalamus. We report that Pirt is highly expressed in the cardiac muscle, the pituitary gland, and the hypothalamus ([Figure 1](#fig1){ref-type="fig"}A). Pirt was not detectable in BAT, suggesting that any involvement in energy expenditure is mediated indirectly, likely through the peripheral nervous system ([Figure 1](#fig1){ref-type="fig"}A). Conversely, the observation that Pirt is highly expressed in the hypothalamus prompted us to further parse the expression pattern in this region, using immunohistochemistry (IHC) on brain slices from WT and Pirt^−/−^ mice ([Figure 1](#fig1){ref-type="fig"}B). Therewith, we identified consistent Pirt protein expression in hypothalamic regions of the arcuate nucleus (ARH), the median eminence (ME), and part of the ventromedial hypothalamic nucleus (VMH). This expression pattern suggests that Pirt might play a role in the central control of energy metabolism -- an implication substantiated by the detection of immunoreactivity suggesting Pirt protein expression in other key hypothalamic regions such as the medial preoptic nucleus (MPO) and the paraventricular hypothalamic nucleus (PVH) ([Supplemental Figure 1A](#appsec1){ref-type="sec"}). Knockout of the Pirt gene and the Pirt protein in the hypothalamus was confirmed by IHC and qPCR ([Figure 1](#fig1){ref-type="fig"}B,C).Figure 1Pirt is expressed in hypothalamic nuclei. Pirt gene expression, displayed as cycle of threshold (CT), in the heart muscle, pituitary gland, hypothalamus, quadriceps muscle, brown adipose tissue (BAT), inguinal white adipose tissue (iWAT), liver, and epididymal white adipose tissue (eWAT) of wild-type (WT) mice (*n* = 6) (A). Immunohistochemistry in the region of the arcuate nucleus (ARH), the median eminence (ME), and part of the ventromedial hypothalamic nucleus (VMH) of brain slices from WT and Pirt^−/−^ (KO) mice (B). Pirt gene expression in the hypothalamus of WT mice compared to Pirt^−/−^ mice (*n* = 5 per genotype) (C). Scale bars in (B) are 100 μm. Data represent mean ± s.e.m. \*\*\**P* \< 0.001 determined by an unpaired two-tailed Student\'s *t*-test comparing WT with Pirt^−/−^ mice. 3V: Third ventricle.Figure 1

3.2. Global ablation of Pirt has subtle effects on energy homeostasis in chow-fed female mice {#sec3.2}
---------------------------------------------------------------------------------------------

To evaluate the role of Pirt in systemic control of energy metabolism, we exposed both male and female Pirt^−/−^ mice and their WT controls to comprehensive metabolic phenotyping. We introduced a gene-environment metabolic stressor by incorporation of a HFHS diet challenge in parallel cohorts of Pirt^−/−^ and WT male and female mice. Pirt deficiency resulted in a marked increase in body weight in female mice maintained on a chow diet ([Figure 2](#fig2){ref-type="fig"}A) without differences in food intake ([Figure 2](#fig2){ref-type="fig"}L). Mirroring the difference in body weight, chow-fed female Pirt^−/−^ mice exhibited a trend of more body fat relative to WT controls ([Figure 2](#fig2){ref-type="fig"}C, *p* = 0.064; [Supplemental Figure 1B](#appsec1){ref-type="sec"}, *p* = 0.053), while lean mass was comparable between genotypes ([Figure 2](#fig2){ref-type="fig"}D). Whereas ablation of Pirt amplified body weight gain in female mice on a normal diet, this effect was annulled when mice were maintained on a HFHS diet ([Figure 2](#fig2){ref-type="fig"}B). Yet, body composition analysis revealed a main effect of genotype on fat mass ([Figure 2](#fig2){ref-type="fig"}C, *p* \< 0.05; [Supplemental Figure 1B](#appsec1){ref-type="sec"}, *p* \< 0.05), while lean mass in female Pirt^−/−^ mice on a HFHS diet was significantly reduced ([Figure 2](#fig2){ref-type="fig"}D, *p* \< 0.05). Aiming to further understand the enhanced weight gain susceptibility in female Pirt^−/−^ mice, we employed indirect calorimetry to analyze energy expenditure, substrate utilization, and locomotion. We did not observe differences in energy expenditure, RER, or locomotor activity between Pirt^−/−^ and WT female mice ([Figure 2](#fig2){ref-type="fig"}I,J,K). Moreover, we failed to measure differences in the expression of thermogenic genes such as Ucp1, iodothyronine deiodinase 2 (Dio2), or PR domain-containing 16 (Prdm16) in the BAT of chow-fed female WT and Pirt^−/−^ mice ([Supplemental Figure 2](#appsec1){ref-type="sec"}). Pirt knockout did not impact body weight in male mice on a standard chow ([Figure 2](#fig2){ref-type="fig"}E) or on a HFHS diet ([Figure 2](#fig2){ref-type="fig"}F). Similarly, chow-fed and HFHS-fed male WT and Pirt^−/−^ mice did not differ with respect to food intake (data not shown) or body composition ([Figure 2](#fig2){ref-type="fig"}G,H; [Supplemental Figure 1C](#appsec1){ref-type="sec"}).Figure 2Sex- and diet-specific effects of Pirt deficiency on energy metabolism. Body weight progression of female wild-type (WT) (black) and Pirt^−/−^ (KO) (grey) mice on a standard chow (A) and high-fat, high-sugar (HFHS) diet (B). Fat mass (C) and lean mass (D) of the female cohorts at 27 weeks of age. Body weight progression of male WT and Pirt^−/−^ mice on a standard chow (E) and HFHS diet (F). Fat mass (G) and lean mass (H) of the male cohorts at 27 weeks of age. Energy expenditure (I), respiratory exchange ratio (RER) (J), and mean locomotor activity (K) of female chow-fed WT and Pirt^−/−^ mice at 27 weeks of age. Average daily food intake in female chow-fed WT and Pirt^−/−^ mice from week 8 to week 25 of age (L). Phenotyping cohorts with *n* = 8 per sex, diet, and genotype. Data represent mean ± s.e.m. Data presented in longitudinal graphs (A,B,E,F,I,J) were analyzed by two-way ANOVA (genotype and time) and data presented in bar graphs (C,D,G,H,K,L) were analyzed by two-way ANOVA (genotype and diet) or an unpaired two-tailed Student\'s *t*-test comparing WT with Pirt^−/−^ mice. ANOVA was followed by Bonferroni post hoc multiple comparison analysis to determine statistical significance. \**P* \< 0.05, \*\**P* \< 0.01 effects of genotype within the diets and ^\$^*P* \< 0.05 main effects of genotype irrespective of diet.Figure 2

3.3. Ablation of Pirt compromises glucose metabolism in female but not male mice {#sec3.3}
--------------------------------------------------------------------------------

In order to determine the role of Pirt in glucose metabolism, we performed an intraperitoneal glucose tolerance test (GTT) in chow-fed and HFHS-fed (18 weeks of exposure) WT and Pirt^−/−^ mice of both sexes. Female Pirt^−/−^ mice maintained on a chow diet displayed an impaired glucose tolerance relative to WT control mice ([Figure 3](#fig3){ref-type="fig"}A,C, *p* \< 0.05 and 0.01 resp.). Corroborating the weight phenotype, the impaired glucose tolerance observed in chow-fed female Pirt^−/−^ mice was abrogated when the female mice were exposed to a HFHS diet; however, the area under the curve of female Pirt^−/−^ mice, irrespective of the feeding regime, was significantly impaired as a main effect of genotype ([Figure 3](#fig3){ref-type="fig"}B,C, *p* \< 0.01). No difference in glucose tolerance between male, chow-fed and HFHS-fed WT and Pirt^−/−^ mice was observed ([Figure 3](#fig3){ref-type="fig"}D--F).Figure 3Female Pirt deficient mice have an impaired glucose tolerance. Blood glucose traces after an intraperitoneal glucose tolerance test in female chow-fed (A) and high-fat, high-sugar (HFHS) diet-fed (B) and male chow-fed (D) and HFHS diet-fed (E) wild-type (WT) (black) and Pirt^−/−^ (KO) (grey) mice with the corresponding area under the curve (AUC) (C,F) at 26 weeks of age. Phenotyping cohorts with *n* = 8 per sex, diet, and genotype. Data represent mean ± s.e.m. Data presented in line graphs (A,B,D,E) were analyzed by two-way ANOVA (genotype and time) and data presented in bar graphs (C,F) were analyzed by two-way ANOVA (genotype and diet) comparing WT with Pirt^−/−^ mice. ANOVA was followed by Bonferroni post hoc multiple comparison analysis to determine statistical significance. \**P* \< 0.05, \*\**P* \< 0.01 effects of genotype within the diets and ^\$\$^*P* \< 0.01 main effects of genotype irrespective of diet.Figure 3

3.4. TRPM8-linked amplification in energy expenditure is Pirt-independent {#sec3.4}
-------------------------------------------------------------------------

Since Pirt is a regulator of TRPM8 signaling [@bib16], we next explored whether TRPM8-induced thermogenesis is compromised in mice lacking Pirt. A single s.c. injection of the TRPM8 super agonist icilin (2 μmol/kg) significantly increased energy expenditure to a similar extent in WT and Pirt^−/−^ mice relative to saline-treated controls ([Figure 4](#fig4){ref-type="fig"}A--C). The amplification in energy expenditure following icilin treatment was independent of locomotor activity ([Figure 4](#fig4){ref-type="fig"}D). Thus, pharmacological activation of TRPM8 increases energy expenditure in a Pirt-independent fashion.Figure 4Pharmacological activation of TRPM8 with icilin induces energy expenditure in wild-type and Pirt^−/−^ mice. Energy expenditure of female chow-fed wild-type (WT) (A) and Pirt^−/−^ (KO) mice (B) after subcutaneous injections of icilin (2 μmol/kg) (grey) or saline control (black) (*n* = 8 per genotype) with respective area under the curve (AUC) after icilin and saline injections (0--90 min) (C) and AUC of locomotor activity in the same period (D). Data represent mean ± s.e.m. \**P* \< 0.05, \*\**P* \< 0.01 determined by an unpaired two-tailed Student\'s *t*-test comparing saline and icilin injections within genotype.Figure 4

4. Discussion {#sec4}
=============

We here examined the impact of global Pirt gene ablation on energy and glucose metabolism in female and male mice fed either chow or high-fat, high-sugar diet. We identified a subtle increase in the susceptibility to develop obesity and glucose intolerance in Pirt^−/−^ female mice on a normal chow diet. This effect was absent when the animals were maintained on a HFHS diet, although fat mass was significantly increased in both lean and DIO female Pirt^−/−^ mice. Male mice deficient for Pirt displayed no differences in glucose or energy metabolism relative to WT controls.

Recent reports describe a regulatory involvement of Pirt in the TRPM8 signaling pathway [@bib16]. Because pharmacological TRPM8 activation induces UCP1-dependent thermogenesis in BAT [@bib10], [@bib13], we hypothesized that the lack of Pirt would impair energy homeostasis. In concordance with the proposed lack of TRPM8 expression in BAT [@bib13], we did not find Pirt expressed in BAT. Thus, any effect of Pirt on BAT thermogenesis is most likely indirect, through neuronal relays, which is in line with the suggested indirect effect of TRPM8 activation on BAT-dependent thermogenesis [@bib13]. Interestingly, we identified, for the first time, a robust Pirt expression in several hypothalamic nuclei. The hypothalamus serves as the central hub for coordinating energy metabolic cues including sensory signals arising from the peripheral nervous system. Accordingly, the hypothalamic Pirt expression points to a possible central integrative function, which instigated us to continue our investigations on the role of Pirt in energy homeostatic control.

Because Pirt is involved in ambient temperature sensing [@bib16], thermoneutral conditions may blunt the physiological role of Pirt. Consequently, we decided to execute the metabolic phenotyping at temperatures below the thermoneutral zone. Only female Pirt^−/−^ mice that were fed a standard chow diet gained significantly more body weight compared to WT mice without detectable differences in food intake, energy expenditure, or locomotor activity. The fact that the female Pirt^−/−^ mice did not display a higher energy expenditure following the separation in body weight could indicate subtle alterations in energy expenditure. Consequently, we assessed thermogenic gene programs in the BAT of female chow-fed WT and Pirt^−/−^ mice but observed no differences. Thus, the inability of female Pirt^−/−^ mice to adequately activate energy expenditure mechanisms does not seem to result from defective BAT-dependent thermogenesis. Female C57Bl/6 mice are reported to have a higher core body temperature, which is associated with an increased oxygen consumption [@bib19], [@bib20], [@bib21], [@bib22]. Pirt deficient mice exhibit defects in cold sensation [@bib16]; the lack of Pirt in female mice on a standard chow diet could thus influence the capability to adjust metabolism to a mild cold stress. This is speculative, as is the ability of HFHS diet-induced thermogenesis to overwrite this susceptibility. Of note, although DIO female Pirt^−/−^ mice did not differ from WT mice with respect to body weight, deficiency of Pirt did result in an altered body composition and relatively more body fat compared to WT mice, supporting the notion that Pirt deficiency results in subtle metabolic defects in females. Additional work is needed to tease out a possible interaction between Pirt in temperature regulation and Pirt in metabolic control. In context, a limitation of this study is that we did not investigate how Pirt deficient mice defend their body temperature at sub-ambient room temperatures and the potentially associated impact on body weight, which should be a relevant focus for future studies on Pirt *in vivo*.

Out of the four cohorts of mice studied here, only the female chow-fed Pirt^−/−^ mice had an impaired glucose metabolism compared to WT mice. Because of a tight relationship between obesity, glucose intolerance, and diabetes [@bib23], we cannot rule out that the impaired glucose tolerance in Pirt^−/−^ female mice is secondary to the increased body weight.

Pirt plays a regulatory role in altering the gating properties of TRPM8 following both cold temperature exposure and menthol application as demonstrated through *in vitro* experiments [@bib16], [@bib18]. We here investigated whether TRPM8 activity also requires Pirt *in vivo*. Thus, we pharmacologically activated TRPM8 receptors with icilin, a TRPM8 super agonist, and monitored energy expenditure in female WT and Pirt^−/−^ mice. Our results show that the icilin-evoked TRPM8-dependent energy expenditure induction is independent of Pirt. Consistent with this notion, divergent pathways downstream of TRPM8 have been reported [@bib18], and more work is now needed to tease out TRPM8-Pirt signaling under diverse physiological challenges. Finally, since Pirt can regulate the function of other TRP channels, including TRPV1 and heat sensing [@bib15], comprehensive investigations of metabolically relevant TRP channels -- in particular those expressed in the hypothalamus -- and their possible interconnectedness with Pirt are warranted.

5. Conclusion {#sec5}
=============

In summary, we here report that Pirt contributes subtle, sex-specific effects on energy and glucose regulation. In contrast to emerging evidence based on *in vitro* studies [@bib16], [@bib18], Pirt does not appear to play a role for TRPM8-stimulated energy expenditure *in vivo*.
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